NCT03843892Approved For Marketing不适用
Expanded Access Use of OFEV (Nintedanib) in Non-IPF Interstitial Lung Disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 6
研究概览
简要总结
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation in this Expanded Access Program (EAP).
研究者
研究点 (6)
Loading locations...
相似试验
No Longer Available
不适用
A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)Lung Diseases, Interstitial (in Pediatric Populations)Childhood Interstitial Lung Disease (chILD)NCT05624281Boehringer Ingelheim
No Longer Available
不适用
An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment OptionsLung Diseases, InterstitialNCT04739150Boehringer Ingelheim
Available
不适用
Individual Patient Compassionate Use of FedratinibMyelofibrosisNCT03723148Celgene
No Longer Available
不适用
89Zr-DFO-girentuximab Expanded Access Program (EAP)Clear Cell Renal Cell CarcinomaNCT06090331Telix Pharmaceuticals (Innovations) Pty Limited
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.